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Objective To carry out epidemiological typing of clinical isolates of Salmonella enterica
serovar Enteritidis by pulsed-field gel electrophoresis (PFGE), random amplified poly-
morphic DNA (RAPD) and analysis of their antibiotic resistance.
Methods Over a 12-month period, 44 Salmonella Enteritidis isolates, recovered from 40
patients admitted to the University Hospital Center of Amiens, France and from three
outpatients, were characterized by the analysis of phenotypic and genotypic traits and
clinical data from medical reports.
Results Forty nontyphoidal salmonellosis episodes were diagnosed in hospitalized
patients (34 episodes of gastroenteritis, two episodes of bacteremia not affecting other
organs, one episodes of bacteremia plus urinary infection, one episodes of bacteremia
plus gastroenteritis, one episodes of chronic colitis plus gastroenteritis and one episode of
peritonitis), and three carriers were observed in outpatients. By means of PFGE, RAPD
and antibiotic susceptibility patterns 44 isolates were subdivided into 16 clonally related
groups. Two of them were predominantly implicated in the course of these infections,
being responsible for two successive waves of infection, while the others were encoun-
tered sporadically.
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I N T R O D U C T I O N
Salmonella enterica serovar Enteritidis has become
the predominant serovar responsible for human
nontyphoidal salmonellosis in many countries [1–
3]. The frequency of S. Enteritidis clinical isolates
obtained in the Bacteriology and Hygiene Labora-
tory of the University Hospital Center of Amiens
has risen steadily since 1988 to become higher than
that of S. Typhimurium from 1991 until now [4].
This change was encountered at the national level
since 1991 [5,7]. The trend continued and the
following values were observed in this study:
51.4% (in 1997), 54.4% (in 1998), and 55% (in
1999) for S. Enteritidis, compared to 24.2% (in
1997), 20% (in 1998) and 27.5% (in 1999) for S.
Typhimurium (in relation to all cases of Salmonella
spp. isolated during these years). It is clear that
serovar Enteritidis currently ranks as the most
common Salmonella serotype isolated from
humans and constitutes a major public-health pro-
blem. A number of studies have shown that the
increasing incidence of gastrointestinal infections
caused by S. Enteritidis may be related to the
ingestion of raw, undercooked or contaminated
eggs or egg products [8,9]. Epidemiological stu-
dies of serovar Enteritidis infections are hampered
by a lack of adequate procedures. Standard meth-
ods, including phenotyping procedures, may not
be discriminative, but use of genotyping techni-
ques such as ribotyping [10], random amplified
polymorphic DNA [11] and pulsed-field gel elec-
trophoresis (PFGE) [10] have proved useful for
discriminating isolates of Salmonella spp. The
aim of this study was to evaluate nontyphoidal
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salmonellosis cases treated in Amiens University
Hospital Center in 1999 and to determine the
epidemiological relatedness between these Salmo-
nella Enteritidis isolates. The study was conducted
by analyzing the phenotypic and genotypic traits
of isolates and the clinical and other features of the
patients.
M A T E R I A L S A N D M E T H O D S
Study patients
Forty-three patients, of whom 22 (51.2%) were
female and 21 (48.8%) were male, presented with
nontyphoidal salmonellosis owing to S. enterica
serovar Enteritidis. Forty cases were inpatients
and three cases were from an outpatients clinic.
Data from medical reports, including age, sex and
underlying diseases, were recorded. All the iso-
lates were sporadic strains isolated throughout
1999 from patients admitted to the different hos-
pital units included in this study. Details of the
study population are given in Table 1. During the
study period, there was no suspicion of S. Enter-
itidis outbreaks and no investigation of common
vehicles of infection or other possible link among
the patients was recorded.
Bacterial isolates and Salmonella Enteritidis
characterization
Forty-four nonduplicate S. Enteritidis isolates,
obtained from January 1999 to December 1999
were studied. Thirty-four were isolated from
stools, four from blood, one from urine, one from
biopsy of the colon and one from a lymph gland
biopsy, from patients with clinically suspected
bacteremia and/or focal infections admitted to
the University Hospital Center, and three from
stools of the patients of the outpatients clinic.
The biochemical profile (biotype) was ascertained
by ID32E system (Bio-Me´rieux, Marcy l’Etoile,
France), using a mini-API instrument reader
(Bio-Me´rieux). All strains were serotyped by the
Kauffmann–White method [12] using agglutina-
tion with specific antisera (Biorad, Marne La
Coquette, France).
Antimicrobial susceptibility test
Isolates were tested by the agar diffusion method
on Mueller-Hinton II agar (Bio-Me´rieux), against
the following antimicrobial agents: ampicillin
(AM: 10 mg), ticarcillin (TIC: 75 mg), piperacillin
(PIP: 75 mg), amoxycillin plus clavulanic acid
(75 þ 10 mg), cephalothin (CF: 30 mg), cefoxitin
(FOX: 30 mg), cefotaxime (CTX: 30 mg), ceftazidime
(CAZ: 30 mg), aztreonam (ATM: 30 mg), gentami-
cin (GN: 15 mg), tobramycin (TM: 10 mg), netilmi-
cin (NT: 30 mg), amikacin (AN: 30 mg), ofloxacin
(OFX: 5 mg), trimethoprim plus sulfamethoxazole
(SXT: 1.25 þ 25.75 mg) (Biorad). Zone diameter of
inhibition and equivalent minimal inhibitory con-
centrations (MIC) were read using the antibiogram
reader I2a ‘SIRSCAN’ (Montpellier, France). The
results were expressed as susceptible (S), inter-
mediate (I), and resistant (R) according to the
critical diameter of inhibition and MIC break-
points established by the Antibiogram Committee
of the French Society for Microbiology [13].
DNA fingerprint preparation and PFGE
DNA for PFGE analysis was prepared using the
GenePath Reagents Kit Group 1 (Bio-Rad Labora-
tories, Ivry sur Seine, France) according to the
manufacturer’s instructions.
Selection of restriction enzymes was based on
the recognition site of the enzymes and the G þ C
content of 50–54% previously reported for Salmo-
nella spp. [14]. SpeI (50-ACTAGT-30 Promega
France, Charbonnie`res, France) was used as the
restriction endonuclease.
PFGE was performed in the contour-clamped
homogeneous electric fields device (CHEF-DRII)
(Bio-Rad Laboratories, Richmond, USA). Genomic
DNA in 1% agarose plugs (low-melting agarose,
Bio-Rad Laboratories) was digested overnight
with 9 UI SpeI per plug with 300 mL of the SpeI
buffer and with the reaction conditions recom-
mended by the manufacturer. Fragments were
separated on 1% molecular biology certified agar-
ose and running was performed according to the
instructions included in the GenePath gel kit (Bio-
Rad Laboratories): 6 V/cm for 18.5 h at 14 8C with
an initial switch time of 5 s and a final switch time
of 40 s at an angle of 120 8C. The lambda ladder
(Bio-Rad Laboratories) was used as the molecular
weight marker. After the run was completed, gels
were stained with an ethidium bromide solution
for 15 min, followed by 60 min of destaining, and
then photographed with UV transilluminator
Quantity-one/Gel DOC 2000TM/Molecular ana-
lyst finger printing (Bio-Rad Laboratories, France).
The restriction endonuclease fragment patterns
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Table 1 Date of isolation, origins, phenotypic and genotypic polymorphisms among Salmonella Enteritidis isolated in University Hospital Centre of Amiens in 1999
Date of
isolation
(mo/day/yr) isolates n8 Care units
Sample
type
Genotyping
Patient characteristics Phenotyping PFGE patterns RAPD patterns
Genomic
groupSex
Age
(years)
Clinical
presentations
Antibiotic
susceptible
profile Spel AQ12 Q11
01/04/99 1 Dermatology blood M 71 Bacteremia a A H K 1
01/04/99 2 Geriatrics urine F 82 Urinary tract
infection and
bacteremia
d A H K 1
01/04/99 3 Geriatrics blood F 82 Urinary tract
infection and
bacteremia
d A H K 1
01/16/99 4 Pediatrics stool M 11 Gastroenteritis d A H K 1
02/19/99 5 Internal Medicine stool F 59 Gastroenteritis d A H K1 1a
04/20/99 6 Pediatrics stool M 8 Gastroenteritis c B H1 L 2
04/20/99 7 Pediatrics stool F 9 Gastroenteritis b A H K 1
05/02/99 8 Outpatients Clinic stool F 3 Medical check up d A H K 1
05/06/99 9 Outpatients Clinic stool M 28 Medical check up d A H M 3
05/10/99 10 Geriatrics stool F 98 Gastroenteritis a C H K 4
05/14/99 11 Pediatrics stool M 11 Gastroenteritis d A H K 1
05/17/99 12 Cardiology Intensive
Care Unit
stool M 74 Gastroenteritis a A1 H K2 1b
05/17/99 13 Blood Diseases stool M 36 Leukemia and
Gastroenteritis
a A H K2 1c
05/18/99 14 Hepatogastroenterology stool F 28 Gastroenteritis a A H K2 1c
05/19/99 15 Internal Medicine stool F 50 Gastroenteritis b A H K2 1c
05/20/99 16 Outpatients Clinic stool F 29 Medical check up d A H K2 1c
06/15/99 17 Internal Medicine stool F 27 Gastroenteritis d A H K3 1d
06/18/99 18 Internal Medicine stool M 17 Gastroenteritis d A H K4 1e
06/27/99 19 Nephrology blood M 55 Bacteremia d A H K2 1c
07/06/99 20 Pediatrics stool M 3 Gastroenteritis d D H K5 5
07/14/99 21 Rhumatology stool F 30 Gastroenteritis d E I k3 6
07/14/99 22 Internal Medicine stool F 62 Gastroenteritis d E I N 7
07/14/99 23 Pediatrics stool M 9 Gastroenteritis d F H O 8
07/15/99 24 Internal Medicine stool F 89 Gastroenteritis d A H O 9
07/15/99 25 General visceral surgery stool F 26 Gastroenteritis d A H O 9
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07/30/99 26 Pediatrics stool F 9 Gastroenteritis d A H2 O 9a
07/30/99 27 Pediatrics stool F 2 Gastroenteritis a A J P 10
07/30/99 28 Internal Medicine stool M 37 Gastroenteritis d A H2 O 9a
08/05/99 29 General visceral surgery ganglionary
biopsy
F 42 Peritonitis d A H2 O 9a
08/16/99 30 Cardiac Surgery stool M 78 Gastroenteritis a A H3 O 9b
08/17/99 31 General visceral surgery stool M 25 Gastroenteritis d G H2 O 11
08/18/99 32 Pediatrics stool F 2 Gastroenteritis d A2 H2 O 9c
08/19/99 33 Pediatric Surgery stool F 6 Gastroenteritis a A1 H2 O 9d
08/20/99 34 Geriatrics stool þ blood M 85 Bacteremia and
Gastroenteritis
a A H2 O1 9e
08/24/99 35 Internal Medicine stool F 33 Gastroenteritis d A3 H2 O1 9f
08/29/99 36 Pediatrics stool M 11 Gastroenteritis d A H3 O1 9g
08/29/99 37 Pediatrics stool M 9 Gastroenteritis d A H3 O1 9g
10/13/99 38 Hepatogastroenterology Biopsy of
colon þstool
F 23 Chronic colitis þ
Gastroenteritis
d A H2 O1 9e
11/04/99 39 Pediatrics stool M 10 Gastroenteritis d A H2 O1 9e
11/05/99 40 Pediatrics stool M 6 Gastroenteritis d A H2 O1 9e
11/05/99 41 Pediatrics stool M 4 Gastroenteritis d A H3 O2 9h
11/18/99 42 Pediatrics stool F 2 Gastroenteritis d A H2 O3 9i
11/25/99 43 General visceral surgery stool F 49 Gastroenteritis d A H3 O3 9j
12/11/99 44 Polyvalent pediatric
intensive
care unit
stool M 2 Gastroenteritis d A H2 O 9a
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were interpreted in accordance with the standards
described previously [15,16].
Preparation and purification of whole-cell DNA
for RAPD
A single colony of each isolate from a blood agar
plate was picked and resuspended in lysis buffer
supplied in the QIAamp DNA Kit (Qiagen S.A.,
Courtaboeuf, France). The suspension was vigor-
ously stirred, digested with 20 mL of proteinase K
solution (20 mg/mL), and incubated at 56 8C for 3
h (vortexing 3 times per hour during the whole
incubation). After incubation, 200 mL of new lysis
buffer was added, mixed and incubated at 70 8C
for 10 min. After this incubation, 200 mL of ethanol
(96–100%) was added, and mixed by pulse-vortex-
ing for 15 s. The mixture was carefully applied to
the QIAamp spin column in a 2-mL collection
tube and centrifuged at 6000  g for 1 min. The
QIAamp spin column was then placed in a clean 2-
mL collection tube; 500 mL of AW1 buffer (QIA-
GEN reagents) was then applied to the QIAamp
spin column and centrifuged at 6000  g for 1 min.
A second wash of the QIAamp spin column was
carried out with 500 mL of AW2 buffer (QIAGEN
reagents), and centrifuged at 20 000  g for 3 min.
The QIAamp spin column was placed in a clean
1.5 mL microcentrifuge tube, then 150 mL of TE
buffer (10 mM Tris-HCl [pH 9], 0.5 mM EDTA) was
added, incubated at room temperature for 1 min
and subsequently centrifuged at 6000  g for 1
min (this step was repeated once). The genomic
eluate was stored at – 20 8C until required.
Random amplification of polymorphic DNA
The primers used to discriminate the S. Enteritidis
isolates were: AQ12 (50-CAG-CTC-CTG-T-30 [GþC:
60%]), and Q11 (50-TCT-CCG-CAA-C-30 [G þC:
60%]) synthesized by DNA technologies Eurogen-
tec (Eurogentec, Seraing, Belgium). Amplification
reactions were in a 20-mL solution containing PCR
buffer 1  (10 mM Tris-HCl [pH 8.3], 50 mM KCl,
200 mM (each) deoxynucleotide triphosphate (ATP,
CTP, GTP, and TTP), 1 mL (each) the 2 primers
(40 mM), 0.2 mL (5 U/mL) of AmpliTaq DNA poly-
merase and 1.6 mM MgCl2 solution (Perkin Elmer,
Roche Molecular Systems, Branchburg, New Jer-
sey, USA). Approximately 20 ng of DNA was
added to the mixture. Amplification was carried
out in a Perkin-Elmer thermal Cycler 60 biomed
(Roche Diagnostics Systems) at 94 8C for 7 min,
then 36 8C for 5 min, followed by 37 cycles (each)
at 72 8C for 1 min, 94 8C for 1 min and 36 8C for 1
min, and a final extension of 72 8C for 5 min, and
after that 4 8C for 5 min. Immediately before start-
ing the program, the sample tray loaded with
strips of capped tubes was rapidly transferred to
the Gene Amp PCR systems 2400 block Perkin-
Elmer (Roche Diagnostics Systems, Meylan, France)
at 97 8C.
An aliquot of 1 mL of each amplification product
was loaded on a 1.5% agarose gel with 1  Tris-
acetate-EDTA buffer (Carlo Erba Reagent, Val de
Reuil, France) and was electrophoresed at 100 V
for approximately 2.5 h (GNA 100 horizontal elec-
trophoresis system, Amersham Pharmacia Biotech,
Orsay, France). The molecular weight marker VI
(Boehringer Mannheim, Meylan, France) whose
sizes ranged from 154 to 2176 basepairs (bp)
was run in parallel with the PCR fingerprint sam-
ples. Gels were stained, destained and analyzed as
described in DNA fingerprint preparation for
PFGE.
R E S U L T S
Patient characteristics
The investigation was carried out on 40 hospita-
lized patients who had totalled 330 patient days
with a mean length of stay of 7.6 days (range 1–
51 days). The mean age of these patients was
31.2 years (range 2–93 years) at the time of hospi-
talization. There were 44 S. Enteritidis infections,
out of which 41 (93.2%) were in inpatients and
three (6.8%) were in outpatients with normal stools
who were considered to be S. Enteritidis carriers.
The most relevant epidemiological and clinical
features are summarized in Table 1. The pediatric
patients had a mean age of 6.5 years (range 2–
11 years). They presented with diarrhea plus fever
but had no underlying disease. The young adults
group had a mean age of 30.7 years (range 17–
49 years). In this group, 11 gastroenteritis episodes
and one episode of primary peritonitis were diag-
nosed, and six patients had predisposing condi-
tions: cholecystectomy (patients 25, 31 and 43),
polyarthritis (patient 21), leukemia (patient 13),
and chronic colitis (patient 38). The elderly
patients group had a mean age of 72.5 years (range
50–93 years). In this group, four gastroenteritis
episodes with bacteremia were diagnosed in
patients with (patients 19 and 23) or without
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(patients 1 and 34) predisposing conditions. Two
patients of this group (patients 10 and 30) had an
underlying disease. The spectrum of the under-
lying disease was wide, but only two patients had
a rapidly fatal prognosis; patient 10 with neoplasia
and previous gastroenteritis and patient 13 with
acute leukemia and previous gastroenteritis. Two
patients with bacteremia, one with a urinary tract
infection and another with primary peritonitis,
were considered as suffering from serious under-
lying diseases. The remaining episodes were cate-
gorized as having nonfatal prognoses.
Genotyping analysis
Digestion with SpeI of chromosomal DNA from
the 44 S. Enteritidis isolates studied produced
seven different patterns of 16–24 fragments ran-
ging in size from 48.5 to 485 Kbp arbitrarily desig-
nated PFGE patterns (PFGEps) A to G. PFGEp A
was predominant (88.6% of total number of iso-
lates), and included 37 isolates (1–5, 7–9, 11–19,
24–30, 32–44) out of which 33 were genetically
indistinguishable, with the same size and number
of fragments (18 in all). This pattern showed some
heterogeneity with patterns displaying two or
three fragment differences. They were considered
to be variant subtypes of the same clone and were
designated A1, A2 and A3. Six PFGEps (B, C, D, E, F
and G) with more than three differences were
considered as unrelated types. Each PFGEp corre-
sponded to one isolate (6, 10, 20, 23 and 31, respec-
tively) except for E which had two isolates (21 and
22) and corresponded to sporadic cases. The
PFGEps found are shown in Figure 1 and Table 1.
By using the primer AQ12 only, the amplified
series were differentiated into three distinct RAPD
types named H, I and J located in the region
between 517 and 2176 bp. RAPD type H included
42 isolates: 23 (1–5, 7–21 and 23–25) were geneti-
cally indistinguishable in number (six in all) and
size of bands. The subtypes, H1, H2 and H3, were
closely related to type H, and were considered as
variants of the same pattern. RAPD patterns I and J
Figure 1 PFGE pattern after complete digestion of the S. enterica serovar Enteritidis Strains using SpeI restriction enzyme.
S. enteritidis isolates numbered 1 to 44. Lane M contains the molecular size marker bacteriophage Lambda ladder. The
separation size range is from 50 Kbp to 500 Kbp. Isolates 1–5, 7–9, 11, 13–19, 24–30, 34, 36–44 appear to be the same strain
(strain A) with isolates 12, 32, 33 and 35 being related strains (strain A1 for isolates 11 and 33; strain A2 for isolate 32 and A3
for isolate 35). Isolates 6, 10, 20–23 and 31 do not appear related to any of others isolates and represent 6 unrelated strains
(strains B, C, D, E, F and G respectively).
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with more than three differences, including iso-
lates 22 and 27, respectively, were considered to be
unrelated types (Figure 2 and Table 1).
With the primer Q11, six different patterns were
identified (K, L, M, N, O and P) with between two
and 12 bands located in the region between 394
and 2176 bp. RAPD-K and RAPD-O consisted of
19 and 21 isolates, respectively, among which eight
isolates of K (1–4, 7, 8, 10 and 11) were genetically
identical and 11 isolates of O (23–26, 28–33 and 44)
also were identical. These patterns also showed
some heterogeneity with patterns exhibiting few
fragment differences. They were considered to be
variant subtypesofpatternsK(K1,K2,K3, K4 andK 5)
and O (O1, O2 and O3). The other four patterns
(L, M, N and P) corresponding to isolates, 6, 9, 22
and 27, respectively, were considered to be unre-
lated types (Figure 3 and Table 1).
By using both primers (AQ12 and Q11), six
distinct patterns (HK, H1L, HM, IN, HO and JP)
were distinguished. RAPD patterns HK (43.2%)
and HO (47.7%) included 19 and 21 isolates,
respectively. The other patterns (H1L, HM, IN
and JP) each corresponded to one isolate and were
considered to be unrelated.
Figure 3 RAPD profiles obtained from amplification of
Salmonella enterica serovar Enteritidis genomic DNA using
Q11 as primer synthetized by DNA Technologies Eurogen-
tec – Belgium. S. Enteritidis isolates numbered 1 to 44 were
differentiated into six different patterns: K, L, M, N, O and
P. RAPD type K and O consisted of 19 and 21 isolates
respectively among which 8 isolates of K (1–4, 7, 8, 10 and
11) were genitically identical and 11 isolates of O (23–26, 28–
33 and 44) also were identical. M, size marker VI: number of
basepairs, 154 to 276 (Boehringer Mannheim, France).
Figure 2 RAPD profiles obtained from amplification of
Salmonella enterica serover Enteritidis genomic DNA using
AQ12 as primer synthetized by DNA Technologies Euro-
gentec – Belgium. S. Enteritidis isolates numbered 1 to 44
were differentiated into three distinct RAPD types named
H, I and J. RAPD type H included 42 isolates of which 23 (1–
5, 7–21 and 23–25) were genetically indistinguishable. M,
size marker VI: number of basepairs, 154 to 276 (Boehringer
Mannheim, France).
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In total, 11 different macrorestriction patterns
were generated among the 44 clinical isolates by
both PFGE and RAPD. Sixteen isolates (1–5, 7, 8
and 11–19) gave an identical pattern (AHK). They
were observed during the first 6 months of the
study (January to June) and 19 other isolates,
giving the pattern AHO (24–26, 28–30, 32–44) were
detected during the second period of study (July to
December) at different times and were considered
as characteristic of the epidemic isolates. Both
these patterns presented some heterogeneity
which corresponded to variant subtypes of the
same clones (AHK1, A1HK2, AHK3, AHK4, AHK5
and AH2O, AH3O, A2H2O, A1H2O, AH2O1,
A3H2O1, AH3O1, AH3O2, AH2O3, AH3O3). Nine
isolates 6, 9, 10, 20–23, 27 and 31 recovered from
different patients gave different patterns (BH1L,
AHM, CHK, DHK5, EHK3, EIN, FHO, AJP and
GH2O, respectively) and were epidemiologically
unrelated (Table 1).
Antimicrobial susceptibility
The susceptibility of S. Enteritidis isolates to dif-
ferent antibiotics was as follows: 12 (27.3%) isolates
were resistant to ampicillin (MIC > 128 mg/L),
and ticarcillin (MIC > 512 mg/L), 6 (13.6%) iso-
lates to piperacillin (MIC range, 64–256 mg/L)
and one (2.2%) isolate to trimethoprim-sulfa-
methoxazole (MIC ¼ 16 mg/L). Four (9%) iso-
lates, two (4.5%) isolates and three isolates (6.8%)
were intermediate to piperacillin (MIC range, 16–
32 mg/L), the combination amoxycillin plus cla-
vulanic acid (MIC > 4 mg/L) and cephalothin
(MIC > 8 mg/L), respectively. All isolates were
susceptible to: cefoxitin [MIC range, 0.50–8 mg/
L], cefotaxime [MIC range 0.03–0.50 mg/L], cefta-
zidime [MIC range, 0.03–2 mgL], aztreonam [MIC
range, 0.06–0.50 mg/L], gentamicin [MIC range,
0.06–0.50 mg/L], tobramycin [MIC range, 0.06–
1 mg/L], netilmicin [MIC range, 0.06–0.50 mg/L],
amikacin [MIC range, 0.02–4 mg/L]), ofloxacin
[MIC range, 0.06–0.25 mg/L].
All isolates were divided into three antimicro-
bial resistance patterns (designated R patterns a to
c): AMR TICR PIPI/R (a), AMR TICR PIPR AMCI CFI
(b), AMR TICR PIPI SXTR (c) and the phenotype (d)
corresponded to isolates which showed full sus-
ceptibility to all antibiotics tested. Within pattern
type AHK, three isolates (1, 13, 14) had phenotype
(a), three (7, 12, 15) had phenotype (b) and 10 (2–5,
8, 11, 16–19) had phenotype (d). Within pattern
type AHO, three isolates (30, 33, 34) had pheno-
type (a), and 16 (24–26, 28, 29, 32, 35–44) had
phenotype (d). Isolates belonging to minor typing
patterns had a distinct antibiotic resistance profile:
(a) for AJP (isolate 27) and CHK (isolate 10) (c) for
BH1L (isolate 6), and (d) for AHM, DHK5, EHK3,
EIN, FHO and GH2O corresponded to isolates 9,
20, 21, 22, 23 and 31, respectively. No significant
correlation was found between typing patterns
and the antibiotic susceptibility pattern.
PFGE, RAPD and the antibiotic susceptibility
patterns subdivided 44 isolates into 16 clonally
related groups. Two of them, GG1 and GG9, were
predominantly implicated in the course of the
study (Figure 4).
Epidemiological investigation
The epidemiological, phenotypical and genotypi-
cal characterization of 44 isolates is shown in
Figure 4 The monthly repartition of the isolates with their
genomic groups (1-11). From January to June, the predo-
minant GG1 plus the GG2,3 and 4 are observed. From July
to December we noted a heterogeneity of genomic groups
with GG9 as predominant.
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Table 1. Distribution of patients over time
revealed two clusters of bacteria. The isolates of
pattern AHK and phenotype d were associated
with a first cluster of ten cases from January to June
1999. Isolates of pattern AHO and phenotype d
were associated with a second cluster of 16 cases
between July and December 1999. Isolates of both
clusters were identified in both inpatients and
outpatients and were most frequently found in
the pediatric group (11 isolates). The other pattern
types were sporadically encountered once, bet-
ween April and May for pattern types BH1L,
AHM, and CHK (genomic groups 2, 3 and 4,
respectively) and between July and August for
pattern types DHK5, EHK3, EIN, FHO, AJP and
GH2O (genomic groups 5, 6, 7, 8, 10 and 11,
respectively) and were finally epidemiologically
unrelated (Figure 4).
D I S C U S S I O N
S. Enteritidis, a major food-borne pathogen, has
recently emerged as a cause of acute gastroenter-
itis worldwide [17]. In the present study, the most
frequent serovars of Salmonella spp., which caused
human salmonellosis in Amiens in 1999, were S.
Enteritidis followed by S. Typhimurium. These
data are in line with those recorded in a Spanish
hospital [18] but differ from our study, in which
positive-d-tartrate S. Paratyphi B was the third
most common serotype [19]. The percentage of
S. Enteritidis-positive blood cultures in this period
was 18%, higher than the percentage of 7%
reported previously in Amiens by Canarelli B
et al. [4] and that of 1.3% in Asturias, by Rodriguez
et al. [18]. A review of S. bacteremia in England and
Wales [20] reported that less than 2% of nonty-
phoid Salmonella isolated from humans were from
blood culture and emphasized that the greatest
number of bloodstream isolates were Enteritidis
and Typhimurium.
Most of our S. Enteritidis isolates were suscep-
tible to the antibiotics tested. Our findings confirm
those of the literature indicating that most isolates
were susceptible to a wide range of antimicrobial
agents [21]. Nevertheless, 27.2% of the isolates
studied were resistant to more than two tested
antibiotics. This rate was lower than those of 35%
reported elsewhere [18]. The R-patterns AMR TICR
PIPI/R AMCI/S observed here would correspond
to TEM-type b-lactamase resistance. Ampicillin
resistance in S. Enteritidis is usually owing to
TEM-type b-lactamase encoded by genes on a
34– 60-, or 100 Mda plasmid [22,23]. The resistance
to trimethoprim-sulfamethoxazole and ampicillin,
ticarcillin was expressed in three isolates. The
literature shows that the resistance to trimetho-
prim-sulfamethoxazole is encoded by genes on the
plasmid or chromosome [23]. It is noteworthy that
bacteremia was recorded for all age groups but did
not show the bimodal distribution, with a higher
incidence at the two extremes, which is usually
reported [24,25]. In our investigation bacteremia
was only observed in the elderly patients. The
relationship between the S. Enteritidis genomic
group and the age group showed that the isolates
belonging to genomic groups (GG1,5,8 and 10) were
observed only in the pediatric group, those of
GG3,6 and 11 in the young adult group and those
of GG4 and 7 in the elderly patients group. The
other isolates belonging to the predominant geno-
mic group (GG1 and GG9) were shared between
the three groups studied.
With respect to focal infections, we found a
single pyelonephritis episode caused by S. Enter-
itidis AHK (GG1) isolate in an 82-year-old female
with bacteremia and two episodes classified as
intra-abdominal infections as a result of S. Enter-
itidis AHO (GG9): one case of peritonitis and one
case of chronic colitis where S. Enteritidis had been
isolated from mesenteric lymph nodes and from a
biopsy of colon, respectively.
In conclusion, it is evident that there was a small
outbreak owing to the successive spread of
two epidemic clones having a common ancestor
during the study period of 1 year. In addition,
interspersed sporadic cases of infection with gene-
tically unrelated strains developed during the
same period. It is also clear that most of the
gastroenteritis episodes with or without bactere-
mia which occur in Amiens from time to time are
caused by S. Enteritidis belonging to predominant
genotypes. In the pediatric group, the illness
occurred regardless of the presence of predispos-
ing factors and/or underlying disease, unlike the
young adults and elderly patients where nonty-
phoidal salmonellosis more frequently affected
patients with some predisposing factor and/or
underlying disease.
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